TrialCancer immunology, immunotherapy : CII2018

Older melanoma patients aged 75 and above retain responsiveness to anti-PD1 therapy: results of a retrospective single-institution cohort study.

Tony Ibrahim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.